Search company, investor...
Immunai company logo

Immunai

immunai.com

Founded Year

2018

Stage

Series B | Alive

Total Raised

$292.7M

Last Raised

$215M | 2 yrs ago

About Immunai

Immunai operates as a biotechnology company. It maps the immune system with single-cell biology and artificial intelligence (AI) to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes. The company was founded in 2018 and is based in New York, New York.

Headquarters Location

430 East 29th Street

New York, New York, 10016,

United States

Compete with Immunai?

Ensure that your company and products are accurately represented on our platform.

Immunai's Products & Differentiators

    Annotated Multi-omic Immune Cell Atlas

    Immunai has annotated and characterized single cells at high resolution to provide the potential for unprecedented insights into the regulation and function of the immune system in disease. AMICA improves as it grows, enabling Immunai to unlock insights currently trapped in partners’ biobanks

Expert Collections containing Immunai

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Immunai is included in 5 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

10,624 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharma Tech

6,809 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

11,233 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma companies and and assistive tech developers.

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Immunai Patents

Immunai has filed 2 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Electronic health records
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/20/2020

9/6/2022

Electronic health records, Genetics, Molecular biology, Health informatics, Biotechnology

Grant

Application Date

8/20/2020

Grant Date

9/6/2022

Title

Related Topics

Electronic health records, Genetics, Molecular biology, Health informatics, Biotechnology

Status

Grant

Latest Immunai News

Holiday reading recommendation: 7 tech leaders using AI for social impact

Apr 11, 2023

The recent calls to stop the development of systems based on artificial intelligence (AI) due to "fundamental risk to humanity" led us to return to interviews with several leaders who make a contribution to humanity thanks to AI technologies. Michael Matias and Betty Elbert 08:16, 11.04.23 The recent call by artificial intelligence (AI) experts to halt the development of the systems based on the technology due to a "fundamental risk to humanity" has led to a widespread debate in the industry. Among the claims that artificial intelligence improves the quality of everyday life by performing routine and even complicated tasks better than humans can, on the other hand, there are those who claim that artificial intelligence will cause, among other things, dramatic privacy risks and will cost workers in their workplace. For the purpose of the discussion, we returned to recent episodes hosted by Michael Matias in the "20 Minute Leaders" podcast with a number of leaders who founded and are currently leading promising startups that base their products on AI technologies for the benefit of humanity. Here are 7 things AI tools soon be able to do that will impact your life: Cure neurological diseases through a smartphone camera: Micha Breakstone, the Co-founder & CEO of NeuraLight.ai The serial entrepreneur Micha Breakstone (Previously Co-Founder & President of Chorus.ai, acquired for $575M by ZoomInfo) Co-Founded NeuraLight out of a strong personal mission to cure the world of neurological diseases following his grandparents' disease in dementia. Together with his co-founder and CTO, Edmund Benami, their startup aims to solve one of the most disturbing problems for all of humanity by diagnosing microscopic biomarkers from eye movements (e.g., during the act of calculating or trying to remember something) that are captured by a standard video camera or smartphone, and thus able to diagnose neurological diseases such as ALS, Alzheimer's and Parkinson's. Helping governments and the private sector make more informed decisions to deal with climate crises: Shimon Elkabetz, the CEO of Tomorrow Following climate crises that have worsened in frequency in recent years and also the increase in the intensity of the damages caused as a result, Shimon Elkabetz, co-founder of Tomorrow and a former officer in the Israeli Air Force, is determined to provide governments and the entire private sector with forecasts with an accuracy of 500 meters that are updated every minute, the tools they need to manage their climate risks (for example, preventing flight cancellations by airlines, improving the service of delivery services, logistical and budget planning of insurance companies, food, etc.). Elkabetz predicts that in the future we will see more ventures on behalf of the private sector in the field of weather intelligence, as he calls it, in a way that private providers will support the technological development of governments on climate issues for the benefit of the general public. Fighting injustice: Evyatar Ben Artzi, co-founder & CEO of Darrow The two lawyers (Ben artzi and the co-founder Elad Spiegelman) who met in their studies and intern together at the Israeli Supreme Court wanted (together with the CTO Gila Hayat) to bring to the court an opportunity to deal more widely with the violations of justice that occur routinely against the general public. The AI system developed by the LegalTech startup Darrow scans the Internet and identifies violations of the law of public interest. Among other things, the system detects violations in the field of consumerism, privacy, and the environment - such as air pollution, leakage of private information, and defective medicines. Law firms use the system to detect violations and take action against the violators, including through class action lawsuits. In an interview with Michael Matias, the lawyer and fighter for justice in spirit, Evyatar Ben Artzi, tells how the technology met the social impact they are fighting to bring to the public and how they faced the challenges in building the platform at the beginning. Improve the chances of success of surgeries: Dotan Asselmann, Co-founder & CTO of Theator Theator stores video information from surgeries and uses computer vision and AI capabilities to identify the best-performed surgeries and also to identify mistakes. The company's product will be used to create summaries of the significant moments from each surgery (like in a sports game), so that doctors can observe at and learn from their surgeries and present them easily to their students, thus enabling better quality training of interns. Dotan Esselman, an expert in computer vision and the CTO of Theator tells us in this episode the challenges in the development of the product and the shared mission of the two co-founders (the CEO of the company, Tamir Wolf, who served as an IDF doctor in the 13 Fleet and a former executive in several start-ups in the field of medical devices, shared in another episode of "20 Minute Leaders" (https://youtu.be/PyesDXk4pDs) how the patient's surgery experience affected him when he was diagnosed with cancer right after the end of round A series of funding for this startup. In the next step, the company intends to create, on the basis of the accumulated information, protocols that present the ultimate surgery, its most successful version, thus enabling even expert doctors who have completed their period as apprentices to learn from each other on a regular and daily basis. And in the future, the company's intention is to use the system to perform intelligent guidance of surgery, for a doctor or for a robot. Get you a promotion: Shay David, Co-Founder, Chairman, & CEO of Retrain.ai Retrain.ai develops an AI platform that maps the skills and training challenges of employees in large organizations undergoing accelerated change processes. First, the platform breaks down the jobs that the organization is looking to fill into the list of tasks included in them, and then into the skills needed to perform these tasks, from no less than 50 thousand skills included in the platform's database. In an interview with Dr. Shay David, the CEO, he talks about the future of the labor market and the digitalization revolution in big companies that caused enormous changes in the fields of health services, department stores, fashion and textile companies, etc. within which new positions are born and others die, Retrain's software is supposed to help corporations understand Which of the existing employees will be able to fill a new position, and who needs one or another training to integrate into it, and accordingly offers such training. Make our water cleaner: Ari Goldfarb, the Co-founder & CEO of KANDO You've probably already heard about KANDO, the company that was responsible for monitoring Covid through the Israeli wastewater, and for them (the Co-founder & COO, Zohar Scheinin), this was just the beginning - the company has an even bigger goal than this, which is to improve the quality of life of people around the world through wastewater. Ari Goldfarb, CEO of Kendo, who led multidisciplinary environmental projects and served as an advisor to the Israeli Ministry of Environment, tells us in this episode about the big data revolution they are leading in the field of wastewater in order to create a global social impact. The smart system which uses big data and AI can provide wastewater network operators with insights into network conditions in real-time. Thanks to the technology, the operators of the network get a complete, easy-to-understand, and continuous picture of what is happening in the sewage system under their responsibility, and thus make more informed decisions to improve the quality of the wastewater and the cleanliness of the streams we bathe in on the weekends, impact the water costs we pay, and of course, lead to an improvement in our health. Find a cure for cancer: Luis Voloch, the Co-Founder & CTO of Immunai Another successful AI-based startup that has been hosted on the "20 Minute Leaders" in the past is Immunai, a company that has set itself an extremely ambitious goal- to map information about cancer within our immune system. Led by Voloch and his Co-founder Noam Solomon (the CEO), the platform measures and maps the immune system with advanced genetic sequencing technology, and shows what exactly is happening inside the human body's immune system, between millions of cells and connections when it actually scans a huge 'bank' of cells that are in different states of health and disease and provides insights that enable the development of new drugs and treatments for cancer. With the help of the tools developed by the company (which already cooperates with one of the largest hospitals in Israel), it is possible to assess the quality of the medicine needed for a certain medical condition and its chances of getting approval from the FDA. In an interview from their offices, the co-founder and CTO, Luis Voloch, a passionate math and data enthusiast, tells Michael Matias about his passion for managing diverse employees including doctors, engineers, data scientists, etc., around the development of an innovative product with tremendous social impact potential.

Immunai Frequently Asked Questions (FAQ)

  • When was Immunai founded?

    Immunai was founded in 2018.

  • Where is Immunai's headquarters?

    Immunai's headquarters is located at 430 East 29th Street, New York.

  • What is Immunai's latest funding round?

    Immunai's latest funding round is Series B.

  • How much did Immunai raise?

    Immunai raised a total of $292.7M.

  • Who are the investors of Immunai?

    Investors of Immunai include Piedmont Investment Advisors, 8VC, Koch Disruptive Technologies, Alexandria Venture Investments, Talos and 11 more.

  • Who are Immunai's competitors?

    Competitors of Immunai include Scailyte and 5 more.

  • What products does Immunai offer?

    Immunai's products include Annotated Multi-omic Immune Cell Atlas.

  • Who are Immunai's customers?

    Customers of Immunai include Baylor University.

Compare Immunai to Competitors

insitro Logo
insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

Holochip Logo
Holochip

Holochip manufactures adaptive polymer singlet lenses that allow adjustability of focal length without changing the location of the lens. This flexibility aims to provide a compact, rugged and reliable solution for utilizing and manipulating light.

Ziwig Logo
Ziwig

Ziwig specializes in the development of a healthcare platform designed to manage the management of endometriosis. The company's platform integrates patients, health specialists, and artificial intelligence and machine learning specialists that help in the possible detection of chronic women's diseases. The company was founded in 2020 and is based in Lyon, France.

DotLab Logo
DotLab

DotLab operates as a women’s healthcare technology company. The company develops a non-invasive test for endometriosis. It was founded in 2016 and is based in San Francisco, California.

Owkin Logo
Owkin

Owkin specializes in artificial intelligence technologies applied to clinical research and developing drugs and treatments for patients. The company empowers researchers in hospitals, universities, and the biopharma industry to understand drug efficacy varies, improve the drug development process, and help identify key drugs and treatments for individual patients to improve patient outcomes. The company delivers a medicine platform that aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The company was founded in 2016 and is based in New York, New York.

BioTuring Logo
BioTuring

BioTuring developed hera, a program for RNA-Seq data analysis, including read alignment, quantifying abundances of transcripts, and detecting gene fusions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.